An	O
HIV	B:C0019682
-	O
tailored	O
quit	O
-	O
smoking	O
counselling	O
pilot	O
intervention	O
targeting	O
depressive	O
symptoms	I:C0086132
plus	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
.	O

An	O
HIV	O
-	O
tailored	B:C2986593
quit	O
-	O
smoking	O
counselling	O
pilot	O
intervention	O
targeting	O
depressive	O
symptoms	I:C0086132
plus	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
.	O

An	O
HIV	O
-	O
tailored	O
quit	O
-	O
smoking	O
counselling	B:C0010210
pilot	O
intervention	O
targeting	O
depressive	O
symptoms	I:C0086132
plus	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
.	O

An	O
HIV	O
-	O
tailored	O
quit	O
-	O
smoking	O
counselling	O
pilot	B:C0031928
intervention	O
targeting	O
depressive	O
symptoms	I:C0086132
plus	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
.	O

An	O
HIV	O
-	O
tailored	O
quit	O
-	O
smoking	O
counselling	O
pilot	O
intervention	B:C0184661
targeting	O
depressive	O
symptoms	I:C0086132
plus	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
.	O

An	O
HIV	O
-	O
tailored	O
quit	O
-	O
smoking	O
counselling	O
pilot	O
intervention	O
targeting	O
depressive	B:C0086132
symptoms	I:C0086132
plus	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
.	O

An	O
HIV	O
-	O
tailored	O
quit	O
-	O
smoking	O
counselling	O
pilot	O
intervention	O
targeting	O
depressive	O
symptoms	I:C0086132
plus	O
Nicotine	B:C1278444
Replacement	I:C1278444
Therapy	I:C1278444
.	O

Cardiovascular	B:C0007222
disease	I:C0007222
(	O
Cardiovascular	O
disease	I:C0007222
)	O
rates	O
among	O
people	O
living	O
with	O
HIV	O
/	O
AIDS	O
(	O
PHAs	O
)	O
are	O
high	O
.	O

Cardiovascular	O
disease	I:C0007222
(	O
Cardiovascular	B:C0007222
disease	I:C0007222
)	O
rates	O
among	O
people	O
living	O
with	O
HIV	O
/	O
AIDS	O
(	O
PHAs	O
)	O
are	O
high	O
.	O

Cardiovascular	O
disease	I:C0007222
(	O
Cardiovascular	O
disease	I:C0007222
)	O
rates	O
among	O
people	B:C0027361
living	O
with	O
HIV	O
/	O
AIDS	O
(	O
PHAs	O
)	O
are	O
high	O
.	O

Rates	O
of	O
cigarette	O
smoking	O
,	O
a	O
leading	O
contributor	O
to	O
Cardiovascular	B:C0007222
disease	I:C0007222
among	O
PHAs	O
,	O
are	O
40	O
-	O
70	O
%	O
(	O
2	O
-	O
3	O
times	O
higher	O
than	O
the	O
general	O
population	I:C0683971
)	O
.	O

Rates	O
of	O
cigarette	O
smoking	O
,	O
a	O
leading	O
contributor	O
to	O
Cardiovascular	O
disease	I:C0007222
among	O
PHAs	O
,	O
are	O
40	O
-	O
70	O
%	O
(	O
2	O
-	O
3	O
times	O
higher	O
than	O
the	O
general	B:C0683971
population	I:C0683971
)	O
.	O

Furthermore	O
,	O
PHAs	O
have	O
high	O
rates	O
of	O
depression	B:C0011570
(	O
40	O
-	O
60	O
%	O
)	O
,	O
a	O
risk	O
factor	I:C0035648
for	O
smoking	O
cessation	O
relapse	O
.	O

Furthermore	O
,	O
PHAs	O
have	O
high	O
rates	O
of	O
depression	O
(	O
40	O
-	O
60	O
%	O
)	O
,	O
a	O
risk	B:C0035648
factor	I:C0035648
for	O
smoking	O
cessation	O
relapse	O
.	O

The	O
current	O
pilot	B:C0031928
study	I:C0031928
examined	O
the	O
effectiveness	O
of	O
a	O
specifically	O
tailored	O
5	O
-	O
session	O
smoking	O
cessation	O
counselling	O
programme	I:C0010210
for	O
PHAs	O
,	O
which	O
addressed	O
depression	O
,	O
in	O
combination	O
with	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
(	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
)	O
in	O
a	O
cohort	O
of	O
PHA	O
smokers	O
(	O
n	O
=	O
50	O
)	O
.	O

The	O
current	O
pilot	O
study	I:C0031928
examined	B:C0332128
the	O
effectiveness	O
of	O
a	O
specifically	O
tailored	O
5	O
-	O
session	O
smoking	O
cessation	O
counselling	O
programme	I:C0010210
for	O
PHAs	O
,	O
which	O
addressed	O
depression	O
,	O
in	O
combination	O
with	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
(	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
)	O
in	O
a	O
cohort	O
of	O
PHA	O
smokers	O
(	O
n	O
=	O
50	O
)	O
.	O

The	O
current	O
pilot	O
study	I:C0031928
examined	O
the	O
effectiveness	O
of	O
a	O
specifically	O
tailored	B:C2986593
5	O
-	O
session	O
smoking	O
cessation	O
counselling	O
programme	I:C0010210
for	O
PHAs	O
,	O
which	O
addressed	O
depression	O
,	O
in	O
combination	O
with	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
(	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
)	O
in	O
a	O
cohort	O
of	O
PHA	O
smokers	O
(	O
n	O
=	O
50	O
)	O
.	O

The	O
current	O
pilot	O
study	I:C0031928
examined	O
the	O
effectiveness	O
of	O
a	O
specifically	O
tailored	O
5	O
-	O
session	O
smoking	O
cessation	O
counselling	B:C0010210
programme	I:C0010210
for	O
PHAs	O
,	O
which	O
addressed	O
depression	O
,	O
in	O
combination	O
with	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
(	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
)	O
in	O
a	O
cohort	O
of	O
PHA	O
smokers	O
(	O
n	O
=	O
50	O
)	O
.	O

The	O
current	O
pilot	O
study	I:C0031928
examined	O
the	O
effectiveness	O
of	O
a	O
specifically	O
tailored	O
5	O
-	O
session	O
smoking	O
cessation	O
counselling	O
programme	I:C0010210
for	O
PHAs	O
,	O
which	O
addressed	O
depression	B:C0011570
,	O
in	O
combination	O
with	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
(	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
)	O
in	O
a	O
cohort	O
of	O
PHA	O
smokers	O
(	O
n	O
=	O
50	O
)	O
.	O

The	O
current	O
pilot	O
study	I:C0031928
examined	O
the	O
effectiveness	O
of	O
a	O
specifically	O
tailored	O
5	O
-	O
session	O
smoking	O
cessation	O
counselling	O
programme	I:C0010210
for	O
PHAs	O
,	O
which	O
addressed	O
depression	O
,	O
in	O
combination	O
with	O
Nicotine	B:C1278444
Replacement	I:C1278444
Therapy	I:C1278444
(	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
)	O
in	O
a	O
cohort	O
of	O
PHA	O
smokers	O
(	O
n	O
=	O
50	O
)	O
.	O

The	O
current	O
pilot	O
study	I:C0031928
examined	O
the	O
effectiveness	O
of	O
a	O
specifically	O
tailored	O
5	O
-	O
session	O
smoking	O
cessation	O
counselling	O
programme	I:C0010210
for	O
PHAs	O
,	O
which	O
addressed	O
depression	O
,	O
in	O
combination	O
with	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
(	O
Nicotine	B:C1278444
Replacement	I:C1278444
Therapy	I:C1278444
)	O
in	O
a	O
cohort	O
of	O
PHA	O
smokers	O
(	O
n	O
=	O
50	O
)	O
.	O

The	O
current	O
pilot	O
study	I:C0031928
examined	O
the	O
effectiveness	O
of	O
a	O
specifically	O
tailored	O
5	O
-	O
session	O
smoking	O
cessation	O
counselling	O
programme	I:C0010210
for	O
PHAs	O
,	O
which	O
addressed	O
depression	O
,	O
in	O
combination	O
with	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
(	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
)	O
in	O
a	O
cohort	B:C0599755
of	O
PHA	O
smokers	O
(	O
n	O
=	O
50	O
)	O
.	O

The	O
current	O
pilot	O
study	I:C0031928
examined	O
the	O
effectiveness	O
of	O
a	O
specifically	O
tailored	O
5	O
-	O
session	O
smoking	O
cessation	O
counselling	O
programme	I:C0010210
for	O
PHAs	O
,	O
which	O
addressed	O
depression	O
,	O
in	O
combination	O
with	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
(	O
Nicotine	O
Replacement	I:C1278444
Therapy	I:C1278444
)	O
in	O
a	O
cohort	O
of	O
PHA	O
smokers	B:C0337664
(	O
n	O
=	O
50	O
)	O
.	O

At	O
6	O
-	O
month	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
,	O
28	O
%	O
of	O
participants	O
demonstrated	O
biochemically	O
verified	O
abstinence	O
from	O
smoking	O
.	O

At	O
6	O
-	O
month	O
follow	O
-	I:C1522577
up	I:C1522577
,	O
28	O
%	O
of	O
participants	B:C0679646
demonstrated	O
biochemically	O
verified	O
abstinence	O
from	O
smoking	O
.	O

This	O
result	B:C2825142
compares	O
favourably	O
to	O
other	O
quit	O
-	O
smoking	O
intervention	O
studies	O
,	O
particularly	O
given	O
the	O
high	O
percentage	O
of	O
HIV	O
+	I:C0019699
smokers	O
with	O
depression	O
.	O

This	O
result	O
compares	O
favourably	O
to	O
other	O
quit	O
-	O
smoking	O
intervention	B:C0184661
studies	O
,	O
particularly	O
given	O
the	O
high	O
percentage	O
of	O
HIV	O
+	I:C0019699
smokers	O
with	O
depression	O
.	O

This	O
result	O
compares	O
favourably	O
to	O
other	O
quit	O
-	O
smoking	O
intervention	O
studies	B:C0008972
,	O
particularly	O
given	O
the	O
high	O
percentage	O
of	O
HIV	O
+	I:C0019699
smokers	O
with	O
depression	O
.	O

This	O
result	O
compares	O
favourably	O
to	O
other	O
quit	O
-	O
smoking	O
intervention	O
studies	O
,	O
particularly	O
given	O
the	O
high	O
percentage	O
of	O
HIV	B:C0019699
+	I:C0019699
smokers	O
with	O
depression	O
.	O

This	O
result	O
compares	O
favourably	O
to	O
other	O
quit	O
-	O
smoking	O
intervention	O
studies	O
,	O
particularly	O
given	O
the	O
high	O
percentage	O
of	O
HIV	O
+	I:C0019699
smokers	B:C0337664
with	O
depression	O
.	O

This	O
result	O
compares	O
favourably	O
to	O
other	O
quit	O
-	O
smoking	O
intervention	O
studies	O
,	O
particularly	O
given	O
the	O
high	O
percentage	O
of	O
HIV	O
+	I:C0019699
smokers	O
with	O
depression	B:C0011570
.	O

At	O
study	B:C0008972
baseline	O
,	O
52	O
%	O
of	O
HIV	O
+	I:C0019699
smokers	O
scored	O
above	O
the	O
clinical	O
cut	O
-	O
off	O
for	O
depression	O
on	O
the	O
Centre	O
for	I:C0679604
Epidemiological	I:C0679604
Studies	I:C0679604
-	I:C0679604
Depression	I:C0679604
(	I:C0679604
CES	I:C0679604
-	I:C0679604
D	I:C0679604
)	I:C0679604
scale	I:C0679604
.	O

At	O
study	O
baseline	O
,	O
52	O
%	O
of	O
HIV	B:C0019699
+	I:C0019699
smokers	O
scored	O
above	O
the	O
clinical	O
cut	O
-	O
off	O
for	O
depression	O
on	O
the	O
Centre	O
for	I:C0679604
Epidemiological	I:C0679604
Studies	I:C0679604
-	I:C0679604
Depression	I:C0679604
(	I:C0679604
CES	I:C0679604
-	I:C0679604
D	I:C0679604
)	I:C0679604
scale	I:C0679604
.	O

At	O
study	O
baseline	O
,	O
52	O
%	O
of	O
HIV	O
+	I:C0019699
smokers	B:C0337664
scored	O
above	O
the	O
clinical	O
cut	O
-	O
off	O
for	O
depression	O
on	O
the	O
Centre	O
for	I:C0679604
Epidemiological	I:C0679604
Studies	I:C0679604
-	I:C0679604
Depression	I:C0679604
(	I:C0679604
CES	I:C0679604
-	I:C0679604
D	I:C0679604
)	I:C0679604
scale	I:C0679604
.	O

At	O
study	O
baseline	O
,	O
52	O
%	O
of	O
HIV	O
+	I:C0019699
smokers	O
scored	O
above	O
the	O
clinical	O
cut	O
-	O
off	O
for	O
depression	B:C0011570
on	O
the	O
Centre	O
for	I:C0679604
Epidemiological	I:C0679604
Studies	I:C0679604
-	I:C0679604
Depression	I:C0679604
(	I:C0679604
CES	I:C0679604
-	I:C0679604
D	I:C0679604
)	I:C0679604
scale	I:C0679604
.	O

At	O
study	O
baseline	O
,	O
52	O
%	O
of	O
HIV	O
+	I:C0019699
smokers	O
scored	O
above	O
the	O
clinical	O
cut	O
-	O
off	O
for	O
depression	O
on	O
the	O
Centre	B:C0679604
for	I:C0679604
Epidemiological	I:C0679604
Studies	I:C0679604
-	I:C0679604
Depression	I:C0679604
(	I:C0679604
CES	I:C0679604
-	I:C0679604
D	I:C0679604
)	I:C0679604
scale	I:C0679604
.	O

HIV	B:C0019699
+	I:C0019699
smokers	O
with	O
depression	O
at	O
study	O
baseline	O
demonstrated	O
quantitatively	O
lower	O
depression	O
at	O
6	O
-	O
month	O
follow	O
-	I:C1522577
up	I:C1522577
with	O
a	O
large	O
effect	O
size	O
(	O
d	O
=	O
1	O
)	O
,	O
though	O
it	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
p	O
=	O
.058	O
)	O
.	O

HIV	O
+	I:C0019699
smokers	B:C0337664
with	O
depression	O
at	O
study	O
baseline	O
demonstrated	O
quantitatively	O
lower	O
depression	O
at	O
6	O
-	O
month	O
follow	O
-	I:C1522577
up	I:C1522577
with	O
a	O
large	O
effect	O
size	O
(	O
d	O
=	O
1	O
)	O
,	O
though	O
it	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
p	O
=	O
.058	O
)	O
.	O

HIV	O
+	I:C0019699
smokers	O
with	O
depression	B:C0011570
at	O
study	O
baseline	O
demonstrated	O
quantitatively	O
lower	O
depression	O
at	O
6	O
-	O
month	O
follow	O
-	I:C1522577
up	I:C1522577
with	O
a	O
large	O
effect	O
size	O
(	O
d	O
=	O
1	O
)	O
,	O
though	O
it	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
p	O
=	O
.058	O
)	O
.	O

HIV	O
+	I:C0019699
smokers	O
with	O
depression	O
at	O
study	B:C0008972
baseline	O
demonstrated	O
quantitatively	O
lower	O
depression	O
at	O
6	O
-	O
month	O
follow	O
-	I:C1522577
up	I:C1522577
with	O
a	O
large	O
effect	O
size	O
(	O
d	O
=	O
1	O
)	O
,	O
though	O
it	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
p	O
=	O
.058	O
)	O
.	O

HIV	O
+	I:C0019699
smokers	O
with	O
depression	O
at	O
study	O
baseline	O
demonstrated	O
quantitatively	O
lower	O
depression	B:C0011570
at	O
6	O
-	O
month	O
follow	O
-	I:C1522577
up	I:C1522577
with	O
a	O
large	O
effect	O
size	O
(	O
d	O
=	O
1	O
)	O
,	O
though	O
it	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
p	O
=	O
.058	O
)	O
.	O

HIV	O
+	I:C0019699
smokers	O
with	O
depression	O
at	O
study	O
baseline	O
demonstrated	O
quantitatively	O
lower	O
depression	O
at	O
6	O
-	O
month	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
with	O
a	O
large	O
effect	O
size	O
(	O
d	O
=	O
1	O
)	O
,	O
though	O
it	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
p	O
=	O
.058	O
)	O
.	O

Furthermore	O
,	O
those	O
with	O
depression	B:C0011570
were	O
no	O
more	O
likely	O
to	O
relapse	O
than	O
those	O
without	O
depression	O
(	O
p	O
=	O
.33	O
)	O
,	O
suggesting	O
that	O
our	O
counselling	O
programme	I:C0010210
adequately	O
addressed	O
this	O
significant	O
barrier	O
to	O
smoking	O
cessation	O
among	O
PHAs	O
.	O

Furthermore	O
,	O
those	O
with	O
depression	O
were	O
no	O
more	O
likely	O
to	O
relapse	O
than	O
those	O
without	O
depression	B:C0011570
(	O
p	O
=	O
.33	O
)	O
,	O
suggesting	O
that	O
our	O
counselling	O
programme	I:C0010210
adequately	O
addressed	O
this	O
significant	O
barrier	O
to	O
smoking	O
cessation	O
among	O
PHAs	O
.	O

Furthermore	O
,	O
those	O
with	O
depression	O
were	O
no	O
more	O
likely	O
to	O
relapse	O
than	O
those	O
without	O
depression	O
(	O
p	O
=	O
.33	O
)	O
,	O
suggesting	O
that	O
our	O
counselling	B:C0010210
programme	I:C0010210
adequately	O
addressed	O
this	O
significant	O
barrier	O
to	O
smoking	O
cessation	O
among	O
PHAs	O
.	O

Our	O
pilot	B:C0031928
study	I:C0031928
indicates	O
the	O
importance	O
of	O
tailored	O
programmes	I:C2986593
to	O
help	O
PHAs	O
quit	O
smoking	O
,	O
the	O
significance	O
of	O
addressing	O
depressive	O
symptoms	I:C0086132
,	O
and	O
the	O
need	O
for	O
tailored	O
counselling	I:C2986593
programmes	I:C2986593
to	O
enhance	O
quit	O
rates	O
among	O
PHAs	O
.	O

Our	O
pilot	O
study	I:C0031928
indicates	O
the	O
importance	O
of	O
tailored	B:C2986593
programmes	I:C2986593
to	O
help	O
PHAs	O
quit	O
smoking	O
,	O
the	O
significance	O
of	O
addressing	O
depressive	O
symptoms	I:C0086132
,	O
and	O
the	O
need	O
for	O
tailored	O
counselling	I:C2986593
programmes	I:C2986593
to	O
enhance	O
quit	O
rates	O
among	O
PHAs	O
.	O

Our	O
pilot	O
study	I:C0031928
indicates	O
the	O
importance	O
of	O
tailored	O
programmes	I:C2986593
to	O
help	O
PHAs	O
quit	O
smoking	O
,	O
the	O
significance	O
of	O
addressing	O
depressive	B:C0086132
symptoms	I:C0086132
,	O
and	O
the	O
need	O
for	O
tailored	O
counselling	I:C2986593
programmes	I:C2986593
to	O
enhance	O
quit	O
rates	O
among	O
PHAs	O
.	O

Our	O
pilot	O
study	I:C0031928
indicates	O
the	O
importance	O
of	O
tailored	O
programmes	I:C2986593
to	O
help	O
PHAs	O
quit	O
smoking	O
,	O
the	O
significance	O
of	O
addressing	O
depressive	O
symptoms	I:C0086132
,	O
and	O
the	O
need	O
for	O
tailored	B:C2986593
counselling	I:C2986593
programmes	I:C2986593
to	O
enhance	O
quit	O
rates	O
among	O
PHAs	O
.	O

